AstraZeneca signs $6.9bn deal with Daiichi Sankyo for cancer portfolio expansion
The British-Swedish pharmaceutical company, AstraZenica, forms a collaboration agreement with Japan’s Daiichi Sankyo to expand its cancer portfolio.
The deal, which is worth US$6.9bn, will see AstraZenica pay for the shared rights for an oncology drug called trastuzumab deruxtecan (DS-8201).
“We believe that trastuzumab deruxtecan could become a transformative new medicine for the treatment of HER2-positive breast and gastric cancers. In addition, it has the potential to redefine breast cancer treatment as the first therapy for HER2-low expressing tumours,” commented Pascal Soriot, CEO of AstraZenica.
“It also has the potential to treat other HER2-mutated or HER2-overexpressing cancers, including lung and colorectal cancers.”
“We are proud to be working with Daiichi Sankyo, a long-term collaborator of AstraZeneca in other disease areas.”
The deal aligns with the company’s science-led strategy in Oncology, which focuses on tumour drivers and resistance, DNA damage response, Immuno-Oncology, and ADCs.
“Trastuzumab deruxtecan is the flagship asset in our oncology pipeline created by our relentless pursuit of science and technology, the most important strengths of our company,” stated George Nakayama, Representative Director, Chairman and Chief Executive Officer of Daiichi Sankyo.
“Through the strategic collaboration with AstraZeneca, a company with a wealth of global experience and expertise in oncology, we will combine our respective skill sets to maximise the value of trastuzumab deruxtecan and accelerate the establishment of our global oncology business.”
“By aiming to provide new treatment options across a wide range of cancers as soon as possible, we will maximise our contribution to patients with cancer and their families around the world.”
Like what you see! Signup for our weekly newsletter